Abstract
The organic cation transporters have emerged as important regulators in human health and diseases. This chapter will discuss the latest studies demonstrating how a sub-group of these transporters, the organic cation transporter-3 (OCT3), would modulate neurodegeneration and neuroprotection in the brain. These roles of OCT3 have been documented in the dopaminegic nigrostriatal system, a pathway that is affected in Parkinson’s disease (PD). Three experimental models of nigrostriatal neurotoxicity will be discussed to illustrate how OCT3 modulate cell viability. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, previously discovered to cause parkinsonism in a group of drug addicts) mouse model, blocking OCT3 function is neuroprotective. However, OCT3 deletion enhances neurotoxicity in the paraquat (a herbicide that increases the risk of developing PD) and methamphetamine mouse models. These observations are consistent with the ability of OCT3 to bi-directionally transport these toxins and consistent with the expression pattern of OCT3 in the brain. Polymorphisms of OCT3 have been reported in humans and this transporter is suggested to be a susceptibility gene contributing to PD.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, et al. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A. 2013;110(27):11199–204.
Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, et al. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A. 2009;106(19):8043–8.
Rappold PM, Cui M, Chesser AS, Tibbett J, Grima JC, Duan L, et al. Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc Natl Acad Sci U S A. 2011;108(51):20766–71.
Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39(6):889–909.
Krusz JC, Koller WC, Ziegler DK. Historical review: abnormal movements associated with epidemic encephalitis lethargica. Mov Disord. 1987;2(3):137–41.
Calne DB, Lees AJ. Late progression of post-encephalitic Parkinson’s syndrome. Can J Neurol Sci. 1988;15(2):135–8.
Langston JW, Ballard P, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979–80.
Bowman AB, Kwakye GF, Herrero Hernández E, Aschner M. Role of manganese in neurodegenerative diseases. J Trace Elem Med Biol. 2011;25(4):191–203.
Tanner CM. Epidemiology of Parkinson’s disease. Neurol Clin. 1992;10(2):317–29.
Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, et al. Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology. 1997;48(6):1583–8.
Hertzman C, Wiens M, Bowering D, Snow B, Calne D. Parkinson’s disease: a case-control study of occupational and environmental risk factors. Am J Ind Med. 1990;17(3):349–55.
Ritz BR, Manthripragada AD, Costello S, Lincoln SJ, Farrer MJ, Cockburn M, et al. Dopamine transporter genetic variants and pesticides in Parkinson’s disease. Environ Health Perspect. 2009;117(6):964–9.
Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Well-water consumption and Parkinson’s disease in rural California. Environ Health Perspect. 2009;117(12):1912–8.
Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. Rotenone, paraquat and Parkinson’s Disease. Environ Health Perspect. 2011;119(6):866–72.
Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogs. Psychiatry Res. 1979;1:249–54.
Tieu K. A guide to neurotoxic animal models of Parkinson’s Disease. Cold Spring Harb Perspect Med. 2011;1:a009316.
Rappold PM, Tieu K. Astrocytes and therapeutics for Parkinson’s disease. Neurotherapeutics. 2010;7(4):413–23.
Javitch JA, D’Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explain selective toxicity. Proc Natl Acad Sci U S A. 1985;82:2173–7.
Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol. 1999;155(2):268–73.
Miller GW, Gainetdinov RR, Levey AI, Caron MG. Dopamine transporters and neuronal injury. Trends Pharmacol Sci. 1999;20(10):424–9.
Namura I, Douillet P, Sun CJ, Pert A, Cohen RM, Chiueh CC. MPP+ (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine- and serotonin-containing neurons. Eur J Pharmacol. 1987;136(1):31–7.
Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24(7):1227–51.
Courousse T, Gautron S. Role of organic cation transporters (OCTs) in the brain. Pharmacol Ther. 2014;14:10.
Grundemann D, Schechinger B, Rappold GA, Schomig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998;1(5):349–51.
Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, et al. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998;273(49):32776–86.
Slitt AL, Cherrington NJ, Hartley DP, Leazer TM, Klaassen CD. Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels. Drug Metab Dispos. 2002;30(2):212–9.
Gasser PJ, Lowry CA, Orchinik M. Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J Neurosci. 2006;26(34):8758–66.
Vialou V, Balasse L, Callebert J, Launay JM, Giros B, Gautron S. Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem. 2008;106(3):1471–82.
Takeda H, Inazu M, Matsumiya T. Astroglial dopamine transport is mediated by norepinephrine transporter. Naunyn Schmiedebergs Arch Pharmacol. 2002;366(6):620–3.
Shang T, Uihlein AV, Van Asten J, Kalyanaraman B, Hillard CJ. 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. J Neurochem. 2003;85(2):358–67.
Inazu M, Takeda H, Matsumiya T. Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes. J Neurochem. 2003;84(1):43–52.
Russ H, Staust K, Martel F, Gliese M, Schomig E. The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia. Eur J Neurosci. 1996;8(6):1256–64.
Schomig E, Russ H, Staudt K, Martel F, Gliese M, Grundemann D. The extraneuronal monoamine transporter exists in human central nervous system glia. Adv Pharmacol. 1998;42:356–9.
Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, et al. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem. 1998;273(26):15971–9.
Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E. Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999;56(1):1–10.
Martel F, Keating E, Calhau C, Grundemann D, Schomig E, Azevedo I. Regulation of human extraneuronal monoamine transporter (hEMT) expressed in HEK293 cells by intracellular second messenger systems. Naunyn Schmiedebergs Arch Pharmacol. 2001;364(6):487–95.
Russ H, Gliese M, Sonna J, Schomig E. The extraneuronal transport mechanism for noradrenaline (uptake2) avidly transports 1-methyl-4-phenylpyridinium (MPP+). Naunyn Schmiedebergs Arch Pharmacol. 1992;346(2):158–65.
Clejan L, Cederbaum AI. Synergistic interactions between NADPH-cytochrome P-450 reductase, paraquat, and iron in the generation of active oxygen radicals. Biochem Pharmacol. 1989;38(11):1779–86.
Bus JS, Gibson JE. Paraquat: model for oxidant-initiated toxicity. Environ Health Perspect. 1984;55:37–46.
Day BJ, Patel M, Calavetta L, Chang LY, Stamler JS. A mechanism of paraquat toxicity involving nitric oxide synthase. Proc Natl Acad Sci U S A. 1999;96(22):12760–5.
Smith JG. Paraquat poisoning by skin absorption: a review. Hum Toxicol. 1988;7(1):15–9.
Grant H, Lantos PL, Parkinson C. Cerebral damage in paraquat poisoning. Histopathology. 1980;4(2):185–95.
Hughes JT. Brain damage due to paraquat poisoning: a fatal case with neuropathological examination of the brain. Neurotoxicology. 1988;9(2):243–8.
Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res. 1999;823(1–2):1–10.
McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, et al. Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis. 2002;10(2):119–27.
Thiruchelvam M, McCormack A, Richfield EK, Baggs RB, Tank AW, Di Monte DA, et al. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson’s disease phenotype. Eur J Neurosci. 2003;18(3):589–600.
Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem. 2002;277(3):1641–4.
Shimizu K, Ohtaki K, Matsubara K, Aoyama K, Uezono T, Saito O, et al. Carrier-mediated processes in blood--brain barrier penetration and neural uptake of paraquat. Brain Res. 2001;906(1–2):135–42.
McCormack AL, Di Monte DA. Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem. 2003;85(1):82–6.
Barlow BK, Thiruchelvam MJ, Bennice L, Cory-Slechta DA, Ballatori N, Richfield EK. Increased synaptosomal dopamine content and brain concentration of paraquat produced by selective dithiocarbamates. J Neurochem. 2003;85(4):1075–86.
Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci. 2005;88:193–201.
Miller GW. Paraquat: the red herring of Parkinson’s disease research. Toxicol Sci. 2007;100(1):1–2.
Cory-Slechta DA, Thiruchelvam M, Di Monte DA. Letter regarding: “Paraquat: the red herring of Parkinson’s disease research”. Toxicol Sci. 2008;103(1):215–6.
LoPachin RM, Gavin T. Response to “Paraquat: the red herring of Parkinson’s disease research”. Toxicol Sci. 2008;103(1):219–21.
Zaczek R, Culp S, Goldberg H, Mccann DJ, De Souza EB. Interactions of [3H]amphetamine with rat brain synaptosomes. I. Saturable sequestration. J Pharmacol Exp Ther. 1991;257(2):820–9.
Zaczek R, Culp S, De Souza EB. Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport. J Pharmacol Exp Ther. 1991;257(2):830–5.
Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci. 1998;18(13):4861–9.
Sulzer D, Chen T-K, Lau YY, Kristensen H, Rayport S, Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995;15:4102–8.
Sulzer D, Maidment NT, Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem. 1993;60(2):527–35.
Scorza MC, Carrau C, Silveira R, Zapata-Torres G, Cassels BK, Reyes-Parada M. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships. Biochem Pharmacol. 1997;54(12):1361–9.
Clausing P, Bowyer JF. Time course of brain temperature and caudate/putamen microdialysate levels of amphetamine and dopamine in rats after multiple doses of d-amphetamine. Ann N Y Acad Sci. 1999;890:495–504.
Kita T, Matsunari Y, Saraya T, Shimada K, O’Hara K, Kubo K, et al. Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice. Int J Dev Neurosci. 2000;18(6):521–30.
Segal DS, Kuczenski R. Behavioral pharmacology of amphetamine. In: Cho AK, Segal DS, editors. Amphetamine and its analogs, Psychopharmacology, toxicology, and abuse. New York: Academic; 1994. p. 115–50.
Ricaurte GA, Sabol KE, Seiden LS. Functional consequences of neurotoxic amphetamine exposure. In: Cho AK, Segal DS, editors. Amphetamine and its analogs, Psychopharmacology, toxicology, and abuse. New York: Academic; 1994. p. 297–313.
Cubells JF, Rayport S, Rajendran G, Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci. 1994;14:2260–71.
Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci. 1999;19(7):2424–31.
Cadet JL, Krasnova IN, Jayanthi S, Lyles J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res. 2007;11(3–4):183–202.
Amphoux A, Vialou V, Drescher E, Bruss M, La Cour CM, Rochat C, et al. Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006;50(8):941–52.
Nakayama H, Kitaichi K, Ito Y, Hashimoto K, Takagi K, Yokoi T, et al. The role of organic cation transporter-3 in methamphetamine disposition and its behavioral response in rats. Brain Res. 2007;1184:260–9.
Kitayama S, Mitsuhata C, Davis S, Wang JB, Sato T, Morita K, et al. MPP+ toxicity and plasma membrane dopamine transporter: study using cell lines expressing the wild-type and mutant rat dopamine transporters. Biochim Biophys Acta. 1998;1404(3):305–13.
Itokawa M, Lin Z, Uhl GR. Dopamine efflux via wild-type and mutant dopamine transporters: alanine substitution for proline-572 enhances efflux and reduces dependence on extracellular dopamine, sodium and chloride concentrations. Brain Res Mol Brain Res. 2002;108(1–2):71–80.
Lazar A, Grundemann D, Berkels R, Taubert D, Zimmermann T, Schomig E. Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3). J Hum Genet. 2003;48(5):226–30.
Aoyama N, Takahashi N, Kitaichi K, Ishihara R, Saito S, Maeno N, et al. Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin Exp Res. 2006;30(10):1644–9.
Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009;124(6):593–605.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Tieu, K. (2016). Organic Cation Transporters as Modulators of Neurodegeneration and Neuroprotection in the Brain. In: Ciarimboli, G., Gautron, S., Schlatter, E. (eds) Organic Cation Transporters. Springer, Cham. https://doi.org/10.1007/978-3-319-23793-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-23793-0_8
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-23792-3
Online ISBN: 978-3-319-23793-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)